- KR₩695bn
- KR₩561bn
- KR₩234bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.34 | ||
| PEG Ratio (f) | 0.81 | ||
| EPS Growth (f) | 18% | ||
| Dividend Yield (f) | 1.5% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.02 | ||
| Price to Tang. Book | 2.03 | ||
| Price to Free Cashflow | 21.01 | ||
| Price to Sales | 2.63 | ||
| EV to EBITDA | 9.45 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.19% | ||
| Return on Equity | 15.2% | ||
| Operating Margin | 18.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 137,836.96 | 160,003.77 | 170,351.23 | 204,464.84 | 233,948.31 | 288,026 | 340,609 | 16.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +92.21 | +0.28 | +8.24 | -9.12 | -5.33 | +60.27 | +11.18 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InBody Co Ltd is a Korea-based company principally engaged in the manufacture and sale of medical devices. The Company is principally engaged in the manufacture and sale of medical devices such as body composition analyzers, blood pressure monitors, home body composition analyzers and height measuring devices. In addition, the Company is also engaged in the supply of management software for accumulating and managing InBody results. The Company distributes its products within domestic market and to overseas markets including the United States, People's Republic of China, Japan, Malaysia, India, Mexico, Australia, Vietnam.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- May 15th, 1996
- Public Since
- December 14th, 2000
- No. of Shareholders
- 9,458
- No. of Employees
- 166
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 13,346,576
- Address
- InBody Bldg., 625, Eonju-ro, Gangnam-gu, SEOUL, 06106
- Web
- https://www.inbody.co.kr/
- Phone
- +82 25013939
- Auditors
- BDO Sunghyun LLC
Latest News for 041830
Upcoming Events for 041830
Q3 2026 InBody Co Ltd Earnings Release
Q4 2026 InBody Co Ltd Earnings Release
InBody Co Ltd Annual Shareholders Meeting
Similar to 041830
Access Bio
Korea Exchange - KOSDAQ
Aligned Genetics
Korea Exchange - KOSDAQ
Alpha AI
Korea Exchange - KOSDAQ
Angel Robotics
Korea Exchange - KOSDAQ
Asta
Korea Exchange - KOSDAQ
FAQ
As of Today at 03:18 UTC, shares in InBody are trading at KR₩52,100. This share price information is delayed by 15 minutes.
Shares in InBody last closed at KR₩52,100 and the price had moved by +81.28% over the past 365 days. In terms of relative price strength the InBody share price has outperformed the FTSE Developed Asia Pacific Index by +32.41% over the past year.
The overall consensus recommendation for InBody is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe InBody dividend yield is 1.15% based on the trailing twelve month period.
Last year, InBody paid a total dividend of KR₩600, and it currently has a trailing dividend yield of 1.15%. We do not have any data on when InBody is to next pay dividends.
We do not have data on when InBody is to next pay dividends. The historic dividend yield on InBody shares is currently 1.15%.
To buy shares in InBody you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩52,100, shares in InBody had a market capitalisation of KR₩695bn.
Here are the trading details for InBody:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 041830
Based on an overall assessment of its quality, value and momentum InBody is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in InBody is KR₩88,667. That is 70.19% above the last closing price of KR₩52,100.
Analysts covering InBody currently have a consensus Earnings Per Share (EPS) forecast of KR₩3,876 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InBody. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +71.45%.
As of the last closing price of KR₩52,100, shares in InBody were trading +22.11% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The InBody PE ratio based on its reported earnings over the past 12 months is 12.34. The shares last closed at KR₩52,100.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
InBody's management team is headed by:
- Gi Cheol Cha - CEO
- Ra Mi Lee - VPR
- Gyeong Ho Yoo - VPR
- Taek Seon Kim - OTH